JP2005535664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535664A5 JP2005535664A5 JP2004519990A JP2004519990A JP2005535664A5 JP 2005535664 A5 JP2005535664 A5 JP 2005535664A5 JP 2004519990 A JP2004519990 A JP 2004519990A JP 2004519990 A JP2004519990 A JP 2004519990A JP 2005535664 A5 JP2005535664 A5 JP 2005535664A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- receptor antagonist
- glucocorticoid receptor
- patient
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims 13
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims 12
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 150000003431 steroids Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- -1 dimethylaminophenyl moiety Chemical group 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 229960003248 mifepristone Drugs 0.000 claims 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- YWROELXZPBSUCO-IYXRBSQSSA-N (2r)-1,2,3,4,4a,4b,5,6-octahydrophenanthrene-2,7-diol Chemical compound C12CCC(O)=CC2=CC=C2C1CC[C@@H](O)C2 YWROELXZPBSUCO-IYXRBSQSSA-N 0.000 claims 1
- ZCAUIZYRNPHJJO-CAMMJAKZSA-N (8s,10s,13s,14s)-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]12)CC3=CC(=O)CC[C@]3(C)C1=CC[C@@]1(C)[C@H]2CCC1 ZCAUIZYRNPHJJO-CAMMJAKZSA-N 0.000 claims 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000037262 Hepatitis delta Diseases 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39366002P | 2002-07-02 | 2002-07-02 | |
| PCT/US2003/021245 WO2004004653A2 (en) | 2002-07-02 | 2003-07-02 | Methods for treating psychosis associated with interferon-alpha therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535664A JP2005535664A (ja) | 2005-11-24 |
| JP2005535664A5 true JP2005535664A5 (enExample) | 2006-10-26 |
Family
ID=30115622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519990A Pending JP2005535664A (ja) | 2002-07-02 | 2003-07-02 | インターフェロン−α治療に関連した精神病を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8476254B2 (enExample) |
| EP (1) | EP1534299A4 (enExample) |
| JP (1) | JP2005535664A (enExample) |
| CN (1) | CN1665515A (enExample) |
| CA (1) | CA2491296C (enExample) |
| WO (1) | WO2004004653A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097606B2 (en) * | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
| DK2114970T3 (da) | 2007-02-02 | 2011-09-19 | Pfizer Prod Inc | Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer |
| EP1987814A1 (en) * | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| US8658128B2 (en) | 2011-02-03 | 2014-02-25 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| US9598459B2 (en) | 2015-08-03 | 2017-03-21 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| NZ778399A (en) | 2019-02-22 | 2024-11-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| EP4157276A4 (en) | 2020-05-27 | 2024-06-12 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2024077169A1 (en) | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| US12433882B2 (en) | 2022-10-28 | 2025-10-07 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| AU5374798A (en) | 1996-12-05 | 1998-06-29 | Bio-Technology General Corporation | Uses of oxandrolone |
| AU747956B2 (en) * | 1997-10-06 | 2002-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| CA2328411C (en) * | 1998-05-15 | 2008-12-16 | Alan F. Schatzberg | Glucocorticoid receptor antagonists for the treatment of dementia |
| AU6508899A (en) * | 1998-10-13 | 2000-05-01 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
| IL142942A0 (en) * | 1998-11-24 | 2002-04-21 | Holis Eden Pharmaceuticals Inc | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other toga viruses |
| US6340696B1 (en) * | 1999-03-31 | 2002-01-22 | The Procter & Gamble Company | Viral treatment |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
-
2003
- 2003-07-02 EP EP03751785A patent/EP1534299A4/en not_active Withdrawn
- 2003-07-02 US US10/519,008 patent/US8476254B2/en active Active
- 2003-07-02 CA CA2491296A patent/CA2491296C/en not_active Expired - Fee Related
- 2003-07-02 CN CN038158116A patent/CN1665515A/zh active Pending
- 2003-07-02 JP JP2004519990A patent/JP2005535664A/ja active Pending
- 2003-07-02 WO PCT/US2003/021245 patent/WO2004004653A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2491296A1 (en) | Methods for treating psychosis associated with interferon-.alpha. therapy | |
| JP2001518509A5 (enExample) | ||
| JP2006508951A5 (enExample) | ||
| JP2006507311A5 (enExample) | ||
| JP2010180236A5 (enExample) | ||
| JP2019163318A5 (enExample) | ||
| ES2219673T3 (es) | Dosificado posologico ciclofasico de hormonas que contienen una antiprogestina y una progestina. | |
| JP2009504157A5 (enExample) | ||
| JP2006527193A5 (enExample) | ||
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| JP2010508275A5 (enExample) | ||
| CN1905885A (zh) | 包含雌激素和孕激素的延长应用组合 | |
| JP2002515453A5 (enExample) | ||
| JPH0395121A (ja) | 前更年期のホルモン異常の治療用、更年期のホルモン補充療法用、アンドロゲン誘引性障害の治療用および避妊用医薬 | |
| CA2504697A1 (en) | Methods for treating migraine | |
| RU2007130700A (ru) | Комбинация соединений метилксантина и стероидов для лечения хронических распираторных заболеваний | |
| JP2024129140A5 (enExample) | ||
| JP2003505336A5 (enExample) | ||
| JP2010507685A5 (enExample) | ||
| RU2020113341A (ru) | Способ и композиция для лечения вирусной инфекции | |
| JP2005519893A5 (enExample) | ||
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| CA2483855A1 (en) | Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") | |
| JP2007505829A5 (enExample) | ||
| HRP20140257T4 (hr) | Uporaba ciklesonida za liječenje bolesti dišnih puteva |